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Abstract
Background: Recently, human germinal center-associated lymphoma (HGAL) gene protein has been proposed as
an adjunctive follicular marker to CD10 and BCL6.
Methods: Our aim was to evaluate immunoreactivity for HGAL in 82 cases of follicular lymphomas (FLs) - 67 nodal,
5 cutaneous and 10 transformed - which were all analysed histologically, by immunohistochemistry and PCR.
Results: Immunostaining for HGAL was more frequently positive (97.6%) than that for BCL6 (92.7%) and CD10
(90.2%) in FLs; the cases negative for bcl6 and/or for CD10 were all positive for HGAL, whereas the two cases
negative for HGAL were positive with BCL6; no difference in HGAL immunostaining was found among different
malignant subtypes or grades.
Conclusions: Therefore, HGAL can be used in the immunostaining of FLs as the most sensitive germinal center
(GC)-marker; when applied alone, it would half the immunostaining costs, reserving the use of the other two
markers only to HGAL-negative cases.
Background
Follicular lymphoma (FL) is the commonest form of
indolent B-cell lymphomas and the second most fre-
quent type of non-Hodgkin’sl y m p h o m a( N H L )i nw e s -
tern countries [1]. Biologically, FL represents the
neoplastic equivalent of the normal germinal center
(GC) reaction, recapitulating the reactive follicles cellu-
lar composition [2]. An “in situ” phase is known for FL
in which neoplastic cells are confined to GCs [3]; when
it becomes invasive, lymphoma expands follicles and
extends into the interfollicular areas acquiring variable
architectural patterns in which neoplastic follicles can
be crowded or spaced apart, irregular, coalesced, serpigi-
nous, confluent, or serrated; they can show mantle or
marginal zone differentiation; less frequently they have a
predominantly diffuse pattern of growth [4]. FL cells
typically express B-cell markers (CD19, CD20, CD22,
and CD79a), together with GC-markers (CD10 and
BCL6), and have monotypic surface immunoglobulin. At
molecular level, they have clonally rearranged, hypermu-
t a t e di m m u n o g l o b u l i ng e n e s[ 1 ]a n du pt o9 5 %c o n t a i n
a translocation between chromosomes 14 and 18, invol-
ving immunoglobulin heavy chain (IGH@) at 14q32 and
BCL2 at 18q21 [5-14]. As a consequence of the translo-
cation, FL generally exhibits ectopic BCL2 expression.
Recently, human germinal center-associated lym-
p h o m a( H G A L )g e n ep r o t e i n ,a l s ok n o w na sg e r m i n a l
center expressed transcript-2 (GCET2), has been pro-
posed as an adjunctive GC-marker which can be
detected in benign and malignant follicles [4,15,16].
HGAL has been originally described by Lossos et al.
(2003) [15] who identified the gene by conducting a
search for genes predicting outcome in large B-cell lym-
p h o m a( L B C L ) .H G A Li sah i g h l ye v o l u t i o n a r yc o n -
served gene with marked similarity to the mouse GC
gene, M17. Evaluated by RT-PCR among normal tissues,
a high mRNA expression was found in GC lymphocytes,
spleen in humans and mice, compared to other tissues,
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poietic organs HGAL gene was not expressed, except in
lung. HGAL functions as an adaptor protein with a poten-
tial regulatory role and mediate some IL-4 effects during
physiologic response. IL-4 is a growth factor promoting
GC B-cell differentiation into memory B cells and the
absence of IL-4 enhances the GC reaction in secondary
immune responses. HGAL expression in memory B cells,
though at lower levels than in GC lymphocytes, provides
indirect support for the involvement of HGAL in the dif-
ferentiation from GC to memory B cells. Examination of
HGAL mRNA expression in malignant cell lines revealed
variable expression in B-cell NHL cell lines, minimal
expression in Jurkat T cells, and no expression in non-
lymphoid HL60 and K562 cell lines. When analyzed in a
spectrum of NHL tumor specimens, HGAL expression is
high in all FL and low in all chronic lymphocytic leukemia,
in all T lymphoblastic lymphoma and in most mantle cell
lymphoma (MCL) specimens. A single MCL specimen
that demonstrated high HGAL expression, was peculiar
for the high content of normal GC. HGAL immunostain-
ing is present in 100% of Burkitt lymphomas, in 87.5% of
mediastinal large B lymphomas, and in 68% of DLBCLs
and also Hodgkin’s lymphomas appeared HGAL positive
(70.5% of Lymphocyte-predominant and 72% of classical
Hodgkin lymphomas) [16]. Application of HGAL immu-
nostaining is also useful in diagnosing primary cutaneous
B-cell lymphomas (CFL) [17] and defining prognosis of
diffuse large B-cell lymphomas (DLBCL) [15].
In this study, we analyzed HGAL immunostaining in
our series of FL which were all studied histologically, by
immunohistochemistry for CD10, BCL6, BCL2 and
Ki67-antigen expression, and by PCR for B-cell clonality
and MBR-BCL2/JH rearrangement.
Methods
Pathological samples
Cases with a FL histological diagnosis were selected from
the complete list of histological diagnoses performed at
the Department of Anatomic Pathology at the University
Hospital in Ancona (Italy), between 1996 and 2009. For-
malin-fixed and paraffin-embedded tissue blocks were
retrieved to perform morphological evaluation and
immunohistochemical studies. Overall, the series was
composed by 82 cases. The histology was reviewed
according to the World Health Organization (WHO)
Classification of lymphomas revised in 2008 [2]; the pat-
tern of growth and the histologic grade were defined in
each case, except for cutaneous lymphomas. Institutional
Review Board approval was obtained for our study.
Immunohistochemical analysis
Immunohistochemical analyses were performed on par-
affin blocks. Conventional 6-μm-thick histological
sections were obtained with a microtome and mounted
on slides pretreated with poly-l-lysine (Sigma Chemicals,
St Louis, MO). Slides were then deparaffinised and rehy-
drated in ethanol and xylene. Two antigen retrieval
methods were applied, 1) by incubating sections with a
Tris-EDTA solution, pH 9.0, at 95-98°C for 25 min
before staining with antibodies against BCL2, BCL6,
CD10, and 2) by incubating sections with 0.01 M citrate
buffer solution, pH 6.0, for 15 min before staining with
antibodies against Ki67 and HGAL. After washing in
H2O and then in Tris-buffer solution, sections were
incubated with the following monoclonal antibodies:
anti-BCL2 (clone 124, dil. 1:100, Dakocytomation,
Milan, Italy); anti-BCL6 (clone PG-B6p, dil. 1:10, Dako-
cytomation, Milan, Italy); anti-CD10 (clone 56C6, dil.
1:30, Novocastra, Laboratories, New Castle, UK); anti-
Ki67-antigen (clone Mib-1, dil. 1:80, Dakocytomation,
Milan, Italy), and with the polyclonal anti-HGAL (dil.
1:400, Sigma-Aldrich, Milan, Italy). Incubations were
carried out in humidified atmosphere at room tempera-
ture for 1 hour. The reaction was revealed using the
streptavidin-biotin-peroxidase technique (Dako-Envision
Plus/HRP peroxidase kit, Dakocytomation, Milan, Italy).
Sections were then incubated with 3,3’-diaminobenzi-
dine (0.05 diaminobenzidine in 0.05 M Tris buffer, pH
7.6 and 0.01% hydrogen peroxide; Sigma-Aldrich, Milan,
Italy), counterstained with Mayer hematoxylin (Bio-
Optica SpA, Milano, Italy) and cover-slipped with Para-
mount. Reactive tonsil tissue was used as positive con-
trols for GC-markers and staining with omission of the
primary antibody was performed as negative control.
The original slides immunostained for commonly used
markers in lymphoma diagnostics, like CD20, CD3, CD5,
BCL1/Cyclin D1, immunoglobulin light chains, CD21,
CD23, were reviewed; when not available or not easily
interpreted, the immunostaining was done or repeated.
The number of HGAL, BCL6, BCL2, CD10, and Ki67-
antigen immunoreactive cells was counted among at
least 500 cells in the more representative fields by using
a light microscope at 250× magnification and expressed
as percentage. Counting was repeated three times; the
obtained mean values were considered for further analy-
sis. For Ki67-antigen a three-point scale was used: low
proliferative index for positive values ≤ 25%, intermedi-
ate proliferative index for > 25 and ≤ 50%, high prolif-
erative index for values > 50%. HGAL, BCL6, BCL2, and
CD10 positivity of immunostaining was then classified
with a two-point scale: negative (-) for absence of
immunostaining or positivity in less than 20% of positive
cells; positive (+) for immunostaining in more than 20%.
For BCL2 and BCL6, the immunostaining was consid-
ered only in the B-cell population, by comparing it with
the CD3 staining in order to avoid the T-cell compo-
nent marked by BCL2 and by BCL6.
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Molecular analyses were performed on genomic DNA
extracted by paraffin blocks. DNA samples were ampli-
fied by PCR according to the already published methods
for the FR3 and FR2 immunoglobulin heavy chain gene,
for the beta-globin gene and MBR-BCL2/JH rearrange-
ment [18-20]. PCR products were run on polyacrilamide
gels and visualized by ethidium bromide staining.
Statistical analysis
Data were entered into the SPSS statistical program
(SPPS Inc., Chicago, IL) in a PC. Data were expressed as
mean and range for continuous variables and by fre-
quency tabulations for categorical variables. Differences
between groups were analyzed by the c
2 test (or Fisher’s
exact test) for contingency tables and by ANOVA test
for numerical variables. Statistical significance was set at
p < 0.05.
Results
Clinical, histological, phenotypical and molecular find-
ings in the present series of FL are summarized in
Table 1. The diagnosis of FL was confirmed in all 82
cases retrieved from the archives: 77 were nodal FL, of
w h i c h6 7w e r eo n l yc o n s t i t u t e db yF La n d1 0s h o w e d
FL in combination with a LBCL; the last 5 cases were
cutaneous FL which appeared negative for extra-cuta-
neous disease at the diagnosis and during the follow-up
and were therefore considered primary CFL.
No difference for age and gender was found among
the 3 subgroups ("pure” F L :2 8M ,3 9 F ,m e d i a na g e5 9
yrs; FL in combination with LBCL: 5 M, 5 F, median
age 54 yrs; primary CFL: 3 M, 2 F, median age 53 yrs).
Of the nodal FL cases, the most numerous group were
those showing grade 2 with a predominantly nodular
pattern. Marginal zone differentiation was seen only in
this group (7 cases, 9.9%). Six cases showed an “in situ”
pattern: in all, the lesion was incidentally discovered;
they were 3 males and 3 females, with no difference in
age compared to the other subgroups of FL (median
age, 61.5, range 43-79). The lesion was diagnosed during
the pathological staging of epithelial neoplasms in regio-
nal lymph nodes in 4 cases (three women with breast
carcinomas and the lesion involving the axillary lymph
nodes, and one man with gastric cancer, with the lesion
involving the peri-gastric lymph nodes). In the other 2
cases the lesion was found in slightly enlarged inguinal
lymph nodes excised during vascular surgery. In all
cases, in lymphoid tissue devoid of metastases or any
other destructive process, besides normal looking folli-
cles, a variable number of germinal centers, ranging
from few to the majority, showed partial or total substi-
tution by small B-lymphoid cells with centrocyte appear-
ance, immunoreactive for CD10 and BCL2 in all cases,
for BCL6 in 3 cases, and with a mean Ki67-index of 5%;
in all cases the cell infiltrate did not show tendency to
invade the interfollicular areas (Figure 1a, b, c). Cyto-
plasmic HGAL staining was confined to the atypical
GCs with a stronger intensity in small atypical cells with
strong staining for BCL2 (Figure 1d). The immunostain-
ing for BCL2 was intense and strong in all cases. The
difference of Ki67 proliferation index was statistically
significant compared to the other invasive FL (ANOVA
test, p = 0.003). According to WHO recommendations,
patients were staged, but they did not receive any treat-
ment as no evidence of “overt” FL elsewhere was found.
By PCR analysis, four cases showed either monoclonal
IGH@ gene rearrangement (2) or MBR-BCL2/JH rear-
rangement (2).
The other 61 nodal “pure” FL (Figure 2a) stained more
frequently for BCL6 (96.7%) than for CD10 (90.1%);
staining for both GC-markers was detected in 53 cases
Table 1 Clinical, histological, phenotypical and molecular
findings in the series of 82 FL
Gender F 46
M3 6
Age Median 58 Range 20-88
Type of FL Nodal FL 67
Combined FL
+DLBCL
10
Cutaneous 5
Pattern “In situ neoplasia” 6 (7.8%)
Nodular 62 (80.5%)
Nodular and diffuse 5 (6.5%)
Diffuse 4 (5.2%)
WHO Grade Grade 1 8 (11.3%)
Grade 2 37 (52.1%)
Grade 3 26 (36.6%)
Marginal differentiation Yes 7 (9.9%)
No 64 (90.1%)
BCL6 Positive 76 (92.7%)
Negative 6 (7.3%)
CD10 Positive 74 (90.2%)
Negative 8 (9.8%)
BCL2 Positive 72 (87.8%)
Negative 10 (12.2%)
Ki67 antigen Low 23
Intermediate 30
High 29
IGH gene rearrangement Monoclonal 66 (80.5%)
Polyclonal 16 (19.5%)
MBR-BCL2/JH
rearrangement
Present 19 (23.2%)/15 (27.3%)
*
Absent 63 (76.8%)/40 (72.7%)
*
* Limited to cases with successful beta-globin gene amplification.
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was found both in the nodular and in interfollicular
components of FL (Figure 2d). In the remaining cases
B C L 6w a sp o s i t i v ei n6a n dC D 1 0i nt w o .B C L 2
positivity was found in 53 cases (86.9%): it ranged from
faint and partial, limited to a thin perinuclear distribu-
tion and recognizable only at higher magnification (Fig-
u r e2 e ) ,t os t r o n ga n dd i f f u s e ,v i s i b l ea tg l a n c ea tl o w
Figure 1 “In situ” follicular neoplasm. The follicle depicted in serial sections shows partial polarization loss and prevalence of small cells (a), all
staining for CD10 (b), strongly for BCL2 (c) and for HGAL (d).
Figure 2 Invasive follicular lymphoma. FL is formed by large nodules with interfollicular invasion (a) showing positive staining for CD10 (b),
BCL6 (c), HGAL (d); the positivity for GC markers are more evident in the nodular component than in the interfollicular areas in this case. BCL2
was moderately and partially expressed (e). Ki67 proliferative index was high (f).
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related with grade (ANOVA test, p < 0.001; Figure 2f).
Molecular tests were positive in 49 cases (80.3%): in 14
both IGH@ gene rearrangement and MBR-BCL2/JH
rearrangement were positive, in the remaining 35 only
the test of clonality was positive.
In 10 cases of nodal FL, there was a variable admix-
ture of LBCL, displayed by the presence of a diffuse
interfollicular infiltrate of cohesive large blasts. For the
purposes of the present study, evaluation of immunos-
tainings in these cases was done only in the areas con-
sidered as FL which mainly coincided with follicular
areas highlighted by networks of dendritic follicular
cells staining either with CD21 or CD23; only in one
case there was also a diffuse areas of FL without cohe-
sive blast clusters, not realizing the pattern of LBCL.
Therefore the pattern in these cases was mainly nodu-
lar. FL cells stained positively for BCL6 and BCL2 in 9
cases and for CD10 in 8. HGAL was positive in all
cases. Mean Ki67-antigen proliferative index was sig-
nificantly higher than in “pure” FL (68.0 vs 31.82;
ANOVA test, p < 0.0001). Molecular tests were posi-
tive in 9 cases (90%): in one case both IGH@ gene
rearrangement and MBR-BCL2/JH rearrangement were
positive, in the remaining 8 only test of clonality was
positive.
In CFL all cases showed staining for CD10, BCL6, and
HGAL, and 4 for stained for BCL2. Ki67 proliferative
index was lower than that of FL combined with LBCL
(ANOVA test, p < 0.001). Only monoclonal IGH@ gene
rearrangement was detected in 4 cases.
The percentage of HGAL-positive cells ranged from 5
to 100% (mean, 64.89 ± 21.10). The number of neoplas-
tic cells stained for HGAL was similar between CFL, FL
and FL combined with LBCL. Applying the cut-off of
20%, 80 cases were considered positive (97.6%) and 2
(2.4%) negative. Immunostaining for HGAL was more
frequently positive than that for BCL6 and CD10; the
cases negative for BCL6 (5) or for CD10 (7) or for both
marker (1) were all positive for HGAL, whereas the two
cases negative for HGAL were positive with BCL6.
Combination of positivity of the three GC-marker is
reported in Table 2.
Discussion
Immunohistochemical analys i si saf u n d a m e n t a la i dt o
morphological examination in the diagnosis of FL and
relies on identification of either CD10 or BCL6 as GC-
markers, and of BCL2 expression as equivalent of the
typical translocation involving BCL2 gene. Normal
polarization loss and abnormal Ki67-antigen proliferative
index, particularly a low index, are both parameters use-
ful in FL distinction from hyperplastic GCs that can be
present in reactive hyperplasia and in other lymphomas
arising in the mantles or in the marginal zone obliterat-
ing normal GCs. The immunostaining elicits also the
recognition as “in situ” follicular neoplasm of germinal
centers with atypical appearance [3]. IGH@-BCL2g e n e
translocation detection is not typically required for diag-
nosis, as the combined morpho-phenotypic analysis is
sufficient in most cases. HGAL gene protein has been
proposed as an adjunctive GC-marker which can be
detected in benign and malignant follicles [4,15,16]. In
our FL series HGAL was more frequently positive
(97.6%) than that BCL6 (92.7%) and CD10 (90.2%); the
cases negative for bcl6 and/or for CD10 were all positive
for HGAL, whereas the two cases negative for HGAL
were positive with BCL6; no difference in HGAL immu-
nostaining was found among different malignant sub-
types or grades. Previous studies have provided data also
on HGAL immunostaining in lymphoma tissues utilizing
as p e c i f i cm o n o c l o n a la n t i b o d ya n dt h et i s s u em i c r o a r -
ray technology: in the study by Natkunam et al. [16]
HGAL was found in a percentage in line with our
results (96.2%). In the subsequent study by Weinberg et
al. [21] on nodal, extranodal and primary FL, HGAL
immunostaining was found in 98% of cases and in simi-
lar proportion in all subtypes; more recently, Younes et
al. have reported a sensitivity of 94% in their series of
FL, stressing the superiority of this marker over the
others to stain higher grade and the interfollicular and
diffuse areas [4]. In cutaneous primary B-cell lympho-
mas HGAL also proved to be very useful in the distinc-
tion between GC-derived and leg-type lymphomas [17].
Compared to HGAL, CD10 has some limitations due to
frequent negativity in FL with high grade or with mar-
ginal differentiation [4,22,23]. BCL6 seems to be a more
Table 2 Combination of GC-marker immunoreactivity in the series of FL
Triple-positive
N.cases (%)
Double-positive
N.cases (%)
Single-positive
N.cases (%)
Groups (N.cases) HGAL/BCL6/CD10 HGAL/BCL6 HGAL/CD10 BCL6 HGAL
In situ FL (6) 3 (50%) - 3 (50%) - -
Nodal FL (61) 53 (87.1%) 4 (6.5%) 2 (3.2%) 2 (3.2%) -
FL+LBCL (10) 8 (80%) 1 (10%) - - 1 (10%)
CFL (5) 5 (100%) - - - -
Total (82) 69 (84.2%) 5 (6.1%) 5 (6.1%) 2 (2.4%) 1 (1.2%)
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higher grade and in the interfollicular and diffuse areas
[24,25]. Our results with CD10 and BCL6 are similar to
those reported by other studies in which BCL6 was
expressed in 94-98% of FL whereas CD10 was expressed
in 78-89% [21,22]. Another study, however, reported a
lower expression for BCL6 (47%) than for CD10 (77%)
[4]. By using only CD10, one could run a potential risk
to misdiagnosing FL as nodal marginal zone lymphoma
(MZL): in their series of originally diagnosed nodal
MZLs based on CD10 negativity, Salama et al. correctly
reclassified 3% of them as FL by applying other GC
markers, including BCL6 and HGAL [26].
By considering literature data and our present find-
ings, we suggest a rational cost-benefit approach to the
phenotyping of FL by changing the historical panel of
BCL6 and CD10. By using only one GC-marker, either
CD10, BCL6 or HGAL, together with BCL2, we could
have the probability to miss GC-phenotype in less than
10% of FL. As the probability seems to be lower for
HGAL (2.4%) than for BCL6 (7.6%) and CD10 (9.7%),
all cases could be tested initially with HGAL, thus
obtaining similar results as the two marker-approach
with CD10 and BCL6. Only in cases negative or doubt-
ful for HGAL, BCL6 and CD10 could be added to
exclude definitively lymphoma GC. This approach
would be useful in several situations, in particular when
FL should be differentiated from MZLs with follicular
colonization and disruption of the GC, as a commer-
cially available marker for marginal zone differentiation
is still lacking [27,28]. The interpretation of HGAL
immunostaining in these circumstances seems to be
easier than that of BCL6 because the latter is expressed
by follicular T-helper lymphocytes. Another marker that
does not stain T cells and might be useful in this setting
as HGAL is the LIM-only transcription factor 2 (LMO2)
[29]; according to a recent study [4], this marker,
although nuclear and easily identifiable, seems to be less
sensitive than HGAL (70% vs 98%), but in other studies
the two markers seems comparable [21].
Nevertheless, we should always be aware of the poten-
tial pitfalls represented by the aberrant HGAL expres-
sion displayed by other non FL lymphomas. As a matter
of fact, although a normal counterpart with a typical
phenotype is postulated for most lymphomas, the anti-
genic expression may overlap rarely among different
types of lymphomas. As CD10 and BCL6, also HGAL
can be expressed aberrantly in MZL and in MCL. In the
first description of HGAL immunostaining, Natkunam
et al. [16] already observed that small subset of lympho-
mas not considered to be of GC derivation also showed
immunostaining for HGAL, like precursor B-acute lym-
phoblastic lymphoma, splenic and nodal MZL, and
plasma cell neoplasms. Furthermore, because nodal
MZLs are thought to arise from histogenetically hetero-
geneous subgroups of marginal zone cells, it is not sur-
prising that a subset of these lymphomas express GC
markers such as BCL6 and HGAL. However, together
with morphologic features and other differentially
expressed immunohistologic markers such as CD10 and
coexpression of CD43, HGAL staining is likely to be
useful in separating FLs from MZLs. Difficult cases can
be finally solved by molecular demonstration of the typi-
cal translocation of FL, particularly when the differential
diagnosis is with MZLs. Despite any possible limitations
of specimen age and fixation method, a higher success
rate is achievable by FISH (56-100%) than by PCR (30-
83%), because FISH is capable of detecting breakpoints
that lie outside the regions covered by the PCR strategy
and because absolute sequence complementarity is not
required [8]. Our series well confirms the PCR limita-
tions, as we found a PCR detection rate about 30% uti-
lizing primers detection only MBR breakpoints; the low
sensitivity would be increased by detecting other less
frequent breakpoints with multiplex PCR.
Conclusions
HGAL can be used in the immunostaining of FLs as the
most sensitive germinal center (GC)-marker; when
applied alone, it would reduce the immunostaining
costs, reserving the use of the other two markers only to
HGAL-negative cases.
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